XML 41 R28.htm IDEA: XBRL DOCUMENT v3.10.0.1

Investment in Surface Pharmaceuticals, Inc. and Agreements - Related Party Transactions (Tables) - Surface Pharmaceuticals [Member]

9 Months Ended

Sep. 30, 2018

Schedule of Condensed Income Statement

The unaudited condensed results of operations information of Surface is summarized below:

		For the
		Nine months
		September 30, 2018
Revenues, net		$	-
Loss from operations			891
Net loss		$	(891	)

Schedule of Condensed Balance Sheet

The unaudited condensed balance sheet information of Surface is summarized below:

		At September 30,
		2018
Current assets		$	20,090
Non current assets			46
Total assets			20,136
Total liabilities			225
Total stockholders’ equity			19,911
Total liabilities and stockholders’ equity		$	20,136

X

- Definition

Tabular disclosure of condensed balance sheet, including, but not limited to, balance sheets of consolidated entities and consolidation eliminations.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 3
-Paragraph i
-Subsection 10

+ Details

Name:	srt_ScheduleOfCondensedBalanceSheetTableTextBlock
Namespace Prefix:	srt_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of condensed income statement, including, but not limited to, income statements of consolidated entities and consolidation eliminations.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 3
-Paragraph i
-Subsection 10

+ Details

Name:	srt_ScheduleOfCondensedIncomeStatementTableTextBlock
Namespace Prefix:	srt_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=IMMY_SurfacePharmaceuticalsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: